India declared cancer capital of the world – Apollo report

India declared cancer capital of the world - Apollo report

Share This Post

India declared cancer capital of the world

India was designated as the “cancer capital of the world” in the 4th edition of Apollo Hospitals’ Health of the Nation Report, which was published on World Health Day 2024.

According to a report by PTI, this study on India’s health situation revealed concerning patterns in non-communicable diseases (NCDs), with a significant increase in cancer incidence around the country.

As per the 4th edition of the Health of Nation Report by Apollo Hospitals, on World Health Day 2024, almost 33% of Indians have pre-diabetes, 66% have pre-hypertension, and 10% are now dealing with depression.

The research emphasizes the alarming increase of non-communicable diseases (NCDs) in India, including cancer, diabetes, hypertension, cardiovascular illnesses, and mental health disorders, all of which have a substantial impact on the country’s health. India is experiencing a significant increase in cancer cases compared to global rates, which has led to the country being referred to as the “cancer capital of the world.”

Moreover, the paper predicts a possible rise in healthcare expenses caused by illnesses such as pre-diabetes, pre-hypertension, and mental health disorders manifesting in younger individuals. The paper highlights the significance of frequent health screenings in reducing blood pressure (BP) and body mass index (BMI) levels, hence lowering the risk of cardiac-related diseases.

The prevalent cancers in India, ranked by frequency, among women are breast, cervix, and ovary, and among men, they are lung, mouth, and prostate. Nevertheless, despite the comparatively younger age at which cancer is diagnosed in India in comparison to other nations, the rates of cancer screening are still disturbingly low, as stated in the hospital’s announcement.

Health screening and unified action are the needs of the hour

The analysis underscores the need for routine health exams to mitigate the likelihood of cardiac-related illnesses through the monitoring of blood pressure and body mass index values. Although there is an increasing recognition of the need for health checks, there is still a requirement to broaden their coverage throughout India.

Dr. Preetha Reddy, Vice Chairperson of Apollo Hospitals, emphasized the significance of collectively combating non-communicable diseases (NCDs). She emphasized the necessity of nationwide endeavors to properly address these diseases through education and tailored preventative healthcare solutions.

“It is imperative for the healthcare ecosystem and the nation to unite and adopt a cohesive approach in order to effectively address non-communicable diseases.” The findings revealed a pressing requirement for prompt therapies to combat, prevent, and reverse the escalating epidemic of cancer, diabetes, hypertension, and obesity, among other conditions. According to Dr. Reddy, there is an urgent requirement to provide education to the general public and develop personalized preventative healthcare strategies.

She advocated for the prioritization of investments in health infrastructure, the promotion of preventative healthcare measures, and the resolution of health inequities, in order to facilitate sustainable development in the health sector.

Dr. Madhu Sasidhar, President and CEO of Apollo Hospitals, emphasized the need for innovation in preventive healthcare and enhanced accessibility. He stressed the importance of using technology to improve illness prevention, increase the accuracy of diagnoses, and develop patient-centered treatment methods.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy